Merck gives diabetes research contract to ChemGenex

By Kirsty Barnes

- Last updated on GMT

Related tags: Medicine, Obesity

Australian biotech company ChemGenex has received a new three-year
R&D contract from pharma giant Merck after the successful
completion of three previous research contracts in target
discovery.

Under the contract, worth $A1 m (€0.6 m), >ChemGenex​ will provide Merck with pre-clinical services in the fields of diabetes, insulin resistance and other diabetes complications, and will investigate new targets such as the SEPS1 (Selenoprotein S) gene.

ChemGenex first pinpointed the SEPS1 gene last year. It was found to play a significant role in regulating inflammation and has since been of great interest to biomedical and pharmaceutical researchers because of an already heightened understanding of the role of inflammation in many human disorders.

It is thought to play a role in a number of complex diseases, including cancer, cardiovascular disease, diabetes, obesity, Alzheimer's disease preeclampsia and various infectious diseases.

"The new agreement gives Merck access to unique capabilities in diabetes research,"​ said Dr. Inge Lues, executive vice president of pre-clinical R&D at >Merck.

"We are very familiar with ChemGenex's animal model and leading edge technical expertise and want to maintain access to these capabilities for pre-clinical development of a number of interesting potential small molecule therapeutics,"​ said Lues.

Related topics: Preclinical Research, Preclinical

Related products

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars